MiNK Therapeutics, Inc. (INKT) stock
INKTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$9.29−0.06 (-0.70%)
Close on Nov 17, 2026Market cap $47.38MP/E –Yield –
MiNK Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
MiNK Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$6.83M. For fiscal 2025 it was -$5.93M. The highest annual figure on record is -$5.93M in fiscal 2025.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$5.93M | – |
| FY2024 | Dec 31, 2024 | -$9.56M | – |
| FY2023 | Dec 31, 2023 | -$15.76M | – |
| FY2022 | Dec 31, 2022 | -$18.87M | – |
| FY2021 | Dec 31, 2021 | -$12.83M | – |
| FY2020 | Dec 31, 2020 | -$8.34M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$2.08M | – |
| Q1 FY2026 | Mar 31, 2026 | -$1.73M | – |
| Q4 FY2025 | Dec 31, 2025 | -$2.07M | – |
| Q3 FY2025 | Sep 30, 2025 | -$941.35K | – |
| Q2 FY2025 | Jun 30, 2025 | -$1.57M | – |
| Q1 FY2025 | Mar 31, 2025 | -$1.34M | – |
| Q4 FY2024 | Dec 31, 2024 | -$1.73M | – |
| Q3 FY2024 | Sep 30, 2024 | -$2.99M | – |
| Q2 FY2024 | Jun 30, 2024 | -$2.29M | – |
| Q1 FY2024 | Mar 31, 2024 | -$2.54M | – |
| Q4 FY2023 | Dec 31, 2023 | -$3.04M | – |
| Q3 FY2023 | Sep 30, 2023 | -$4.21M | – |
| Q2 FY2023 | Jun 30, 2023 | -$4.15M | – |
| Q1 FY2023 | Mar 31, 2023 | -$4.37M | – |
| Q4 FY2022 | Dec 31, 2022 | -$4.43M | – |
| Q3 FY2022 | Sep 30, 2022 | -$5.61M | – |
| Q2 FY2022 | Jun 30, 2022 | -$4.63M | – |
| Q1 FY2022 | Mar 31, 2022 | -$4.20M | – |
| Q4 FY2021 | Dec 31, 2021 | -$1.70M | – |
| Q3 FY2021 | Sep 30, 2021 | -$3.50M | – |
| Q2 FY2021 | Jun 30, 2021 | -$3.42M | – |
| Q1 FY2021 | Mar 31, 2021 | -$4.21M | – |
| Q4 FY2020 | Dec 31, 2020 | -$1.72M | – |
See a number that looks wrong?